← 治験一覧に戻る
BAY 77-1931口腔内崩壊錠の生物学的同等性試験
基本情報
- NCT ID
- NCT03074058
- ステータス
- 完了
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 20
- 治験依頼者名
- Bayer
概要
The primary objective of this study was to establish the bioequivalence of two different tablet formulations containing BAY77-1931. The secondary objectives of this study were to assess the safety and tolerability, as well as to Investigate the plasma lanthanum concentration after BAY 77-1931 ODT 500 mg administration.
対象疾患
Clinical Pharmacology
介入
Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)(DRUG)
Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)(DRUG)
依頼者（Sponsor）
バイエル薬品株式会社(INDUSTRY)